Search Within

Elizabeth Siryeon Won

  1. "2019"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Department of Medicine (6)
  2. Gastrointestinal Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Center for Pancreatic Cancer Research (5)
  5. Hematologic Malignancies, Division of (5)
  6. Biostatistics Service (4)

More Groups

People
  1. David Ilson (6)
  2. David Kelsen (5)
  3. Geoffrey Ku (5)
  4. Yelena Janjigian (5)
  5. David Solit (4)
  6. Jaclyn Hechtman (4)

More People

Years
  1. 2019 (6)
Publications
  1. Journal of Clinical Oncology (3)
  2. Annals of Oncology (1)
  3. Clinical Cancer Research (1)
  4. Lancet Oncology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (1)
  3. Elsevier Science, Inc. (1)
  4. Oxford University Press (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase I/Ib study of crenolanib with ramucirumab (RAM)/paclitaxel (PTX) as second -line therapy (2L tx) for advanced esophagogastric adenocarcinoma (EGA)
    Meeting Abstract

    Greally, M.; Jha, S.; Yoon, S. S.; Li, J.; Desai, A. M.; Won, E.; Kelsen, D. P.; Ilson, D. H.; Janjigian, Y. Y.; Aljallad, K.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer
    Journal Article

    Won, E.; Basunia, A.; Chatila, W. K.; Hechtman, J. F.; Chou, J. F.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Fuchs, C. S.; Shitara, K.; Di Bartolomeo, M.; Lonardi, S.; Al-Batran, S. E.; Van Cutsem, E.; Ilson, D. H.; Alsina, M.; Chau, I.; Lacy, J.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save